Log in

Cytori Therapeutics Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
-0.04 (-1.78 %)
(As of 10/30/2020 12:00 AM ET)
Today's Range
Now: $2.21
50-Day Range
MA: $0.20
52-Week Range
Now: $2.21
Volume38,464 shs
Average Volume915,302 shs
Market Capitalization$48.97 million
P/E RatioN/A
Dividend YieldN/A
Cytori Therapeutics, Inc. is a late stage cell therapy company, which engages in the development of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. It offers the Cytori Nanomedicine, Cytori Cell Therapy, and other clinical trials. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in San Diego, CA.
Read More
Cytori Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.58 out of 5 stars

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolNASDAQ:CYTX



Sales & Book Value

Annual Sales$3.67 million
Book Value$0.35 per share


Net Income$-12,630,000.00
Net Margins-242.60%


Market Cap$48.97 million
Next Earnings DateN/A

Receive CYTX News and Ratings via Email

Sign-up to receive the latest news and ratings for CYTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Cytori Therapeutics (NASDAQ:CYTX) Frequently Asked Questions

How were Cytori Therapeutics' earnings last quarter?

Cytori Therapeutics Inc (NASDAQ:CYTX) released its earnings results on Tuesday, May, 14th. The biotechnology company reported ($0.18) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.20) by $0.02. The biotechnology company earned $0.70 million during the quarter. Cytori Therapeutics had a negative net margin of 242.60% and a negative return on equity of 272.70%.
View Cytori Therapeutics' earnings history

When did Cytori Therapeutics' stock split? How did Cytori Therapeutics' stock split work?

Cytori Therapeutics's stock reverse split before market open on Thursday, May 24th 2018. The 1-10 reverse split was announced on Wednesday, May 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 23rd 2018. An investor that had 100 shares of Cytori Therapeutics stock prior to the reverse split would have 10 shares after the split.

Who are some of Cytori Therapeutics' key competitors?

What other stocks do shareholders of Cytori Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytori Therapeutics investors own include Regulus Therapeutics (RGLS), Inovio Pharmaceuticals (INO), Shire (SHPG), Bank of America (BAC), Exelixis (EXEL), Athersys (ATHX), BCE (BCE), Celldex Therapeutics (CLDX), Synergy Pharmaceuticals (SGYP) and Novavax (NVAX).

Who are Cytori Therapeutics' key executives?

Cytori Therapeutics' management team includes the following people:
  • Marc H. Hedrick, President, Chief Executive Officer & Director
  • Gary S. Titus, Chief Financial Officer
  • Mark T. Marino, Chief Medical Officer & Senior Vice President
  • John K. Fraser, Chief Scientist
  • Russ Havranek, VP-Global Marketing & Business Development

What is Cytori Therapeutics' stock symbol?

Cytori Therapeutics trades on the NASDAQ under the ticker symbol "CYTX."

What is Cytori Therapeutics' stock price today?

One share of CYTX stock can currently be purchased for approximately $2.21.

How big of a company is Cytori Therapeutics?

Cytori Therapeutics has a market capitalization of $48.97 million and generates $3.67 million in revenue each year. Cytori Therapeutics employs 37 workers across the globe.

What is Cytori Therapeutics' official website?

The official website for Cytori Therapeutics is www.cytori.com.

How can I contact Cytori Therapeutics?

Cytori Therapeutics' mailing address is 3020 CALLAN ROAD, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-458-0900 or via email at [email protected]

This page was last updated on 10/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.